日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)

英夫利昔单抗-dyyb(英夫利昔单抗生物类似药)对临床和患者报告结局的影响:一项在美国和加拿大开展的炎症性肠病患者观察性真实世界研究的 1 年随访结果(ONWARD 研究)

Abraham, Bincy; Eksteen, Bertus; Nedd, Khan; Kale, Hrishikesh; Patel, Dipen; Stephens, Jennifer; Shelbaya, Ahmed; Chambers, Richard; Soonasra, Arif

Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis

全球范围内,托法替尼治疗类风湿性关节炎的3年上市后监测经验

Cohen, Stanley; Curtis, Jeffrey R; DeMasi, Ryan; Chen, Yan; Fan, Haiyun; Soonasra, Arif; Fleischmann, Roy

Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses

托法替尼治疗类风湿性关节炎患者的长期放射学和患者报告结局:ORAL Start 和 ORAL Scan 事后分析

Strand, Vibeke; Kavanaugh, Arthur; Kivitz, Alan J; van der Heijde, Désirée; Kwok, Kenneth; Akylbekova, Ermeg; Soonasra, Arif; Snyder, Mark; Connell, Carol; Bananis, Eustratios; Smolen, Josef S

An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective

从美国支付方的角度对托法替尼治疗甲氨蝶呤或1或2种TNF抑制剂后类风湿性关节炎的经济性评价

Claxton, Lindsay; Taylor, Matthew; Soonasra, Arif; Bourret, Jeffrey A; Gerber, Robert A

The role of nurse practitioners in delivering rheumatology care and services: Results of a U.S. survey

护士执业人员在提供风湿病护理和服务中的作用:一项美国调查的结果

Riley, Lydia; Harris, Cindy; McKay, Michele; Gondran, Sue Ellen; DeCola, Paula; Soonasra, Arif